10 February 2025
Swissmedic: Update of the position paper on decentralised clinical trials (DCTs) of medicinal products
Swissmedic and swissethics have comprehensively revised and updated their position paper on decentralised clinical trials (DCTs) of medicinal products, which is now available in version 3.1. New additions include a comparison of Switzerland with the Member States of the European Union regarding the feasibility of various elements of DCTs.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: Haemovigilance Annual Report 2025
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Global regulators call for advancing alternatives to animal testing